ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0433

Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey
Abstract Number: 0602

Use of a Popular Opinion Leader Model to Disseminate Information Virtually About Clinical Trial Enrollment to People of Color with Lupus
Abstract Number: 0974

Use of Disease-Modifying Anti-Rheumatic Drug Associated with Lower Incidence of Anti-Tumor Necrosis Factor Induced Psoriasis in Children with Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis
Abstract Number: 1150

Use of Energy Conversation Strategies as a Result of the Fatigue Management Education for Individuals with Systemic Sclerosis (FAME-iSS)
Abstract Number: 0784

Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America
Abstract Number: 1718

Use of Gonadotropin Releasing Hormone Agonist for Ovarian Preservation in SLE Patients on Cyclophosphamide
Abstract Number: 0389

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States
Abstract Number: 1463

Use of Telemedicine for Follow-up of Lupus Nephritis in the COVID-19 Outbreak: The 6-month Results of a Randomized Controlled Trial
Abstract Number: 1063

Use of Telemedicine for Rheumatology Practice in Queensland, Australia: Experiences Before and During the COVID-19 Pandemic
Abstract Number: 1626

Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis
Abstract Number: 0650

Use, Procurement Cost, and Adverse Events from IVIg Use in Rheumatic Disease
Abstract Number: 1888

Usefulness of 2019 ACR/EULAR Classification Criteria (AECC) for IgG4-Related Disease Differs Between Clinical Phenotypes of IgG4-RD
Abstract Number: 0151

Usefulness of Ultrasound and (FDG) PET/CT to Detect Cranial and Extracranial Artery Involvement in Patients with Suspected Large Vessel Vasculitis
Abstract Number: 1874

Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis
Abstract Number: 0811

Using a Smartphone App to Detect and Characterise Real-Time Patient-Reported Flares in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].